- GSK shares rise as $2.5B cost-cutting plan unveiledAs GSK records $2.4 billion in impairment charges for the second quarter, the U.K. pharma has announced a sweeping restructure designed to save about the same amount of money over the next few years.BioSpace · 1h ago↗ source
- The future of gray-market peptidesTwo days’ worth of debate among FDA advisory committee members and agency staff over whether compounding pharmacies should be able to make seven different peptides left me with some big ...Endpoints · 1h ago↗ source
- STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trialsNew GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term growth.STAT · 1h ago↗ source